NCT02000531View on ClinicalTrials.gov

Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Erlotinib

150 mg oral dose of erlotinib given once daily

DRUG

Chemotherapy

Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)

Trial Locations (11)

101149

Beijing

130012

Changchun

200030

Shanghai

200433

Shanghai

350014

Fuzhou

400038

Chongqing

400042

Chongqing

430023

Wuhan

515041

Shantou

Unknown

Guangzhou

Nanjing

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02000531 - Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | Biotech Hunter | Biotech Hunter